# A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis

> **NCT02561806** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 302 (actual)

## Conditions studied

- Plaque Psoriasis

## Interventions

- **DRUG:** Ixekizumab
- **DRUG:** Ustekinumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02561806
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10
- **Primary completion:** 2016-05
- **Final completion:** 2017-10
- **Target enrollment:** 302 (ACTUAL)
- **Last updated:** 2020-06-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02561806

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02561806, "A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02561806. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*